Proportion and characteristics of screen-detected and non-screen-detected colorectal cancers in Germany

被引:0
作者
Hornschuch, Michel
Schwarz, Sarina
Haug, Ulrike [1 ,2 ]
机构
[1] Leibniz Inst Prevent Res & Epidemiol BIPS, Dept Clin Epidemiol, Achterstr 30, DE-28359 Bremen, Germany
[2] Univ Bremen, Fac Human & Hlth Sci, Bremen, Germany
关键词
Screening; colonoscopy; fecal occult blood test; Germany; SURVIVAL;
D O I
10.2340/1651-226X.2024.40234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Germany has a long-standing colorectal cancer (CRC) screening offer. We aimed to quantify and characterize screen-detected colorectal cancers (sdCRCs) in Germany. Methods: We conducted a cross-sectional study based on a healthcare database covering similar to 20% of the German population; we included CRC patients aged >= 55 years diagnosed in 2010-2018. Patients with a screening colonoscopy or a fecal occult blood test followed by colonoscopy within 180 days before diagnosis were classified as sdCRCs and compared to non-sdCRCs regarding age, stage and comorbidities. Results: In 2018, 25% of male and 22% of female CRC patients were screen-detected. Regarding characteristics of all included CRC cases (N = 82,538), sdCRC patients were younger than non-sdCRCs (average difference men / women: 2.6 / 4.4 years). The proportion of advanced CRC among sdCRCs and non-sdCRCs, respectively, was 33 and 42% in women (men: 36 and 45%). Severe comorbidities were more prevalent in non-sdCRCs compared to sdCRCs (e.g. in male / female patients aged 65-74: 35% vs. 27% / 26% vs. 19%). Prevalences of hypertension and obesity were similar in both groups. Interpretation: Our study suggests that about one fourth of CRCs in Germany are screen-detected. Among patients with non-sdCRC, not only advanced stage but also severe comorbidity was more common than in sdCRCs.
引用
收藏
页码:924 / 931
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 2017, KREBS DEUTSCHLAND 20
[2]  
Asendorf M, 2022, Deutsche Gesellschaft fur Medizinische Informatik, Biometrie und Epidemiologie eV, V18, pDoc02
[3]   Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis [J].
Boakye, Daniel ;
Rillmann, Bettina ;
Walter, Viola ;
Jansen, Lina ;
Hoffmeister, Michael ;
Brenner, Hermann .
CANCER TREATMENT REVIEWS, 2018, 64 :30-39
[4]   Survival of patients with symptom- and screening-detected colorectal cancer [J].
Brenner, Hermann ;
Jansen, Lina ;
Ulrich, Alexis ;
Chang-Claude, Jenny ;
Hoffmeister, Michael .
ONCOTARGET, 2016, 7 (28) :44695-44704
[5]   Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study [J].
Cardoso, Rafael ;
Guo, Feng ;
Heisser, Thomas ;
De Schutter, Harlinde ;
Van Damme, Nancy ;
Christina Nilbert, Mef ;
Julie Tybjerg, Anne ;
Bouvier, Anne-Marie ;
Bouvier, Veronique ;
Launoy, Guy ;
Woronoff, Anne-Sophie ;
Cariou, Melanie ;
Robaszkiewicz, Michel ;
Delafosse, Patricia ;
Poncet, Florence ;
Walsh, Paul M. ;
Senore, Carlo ;
Rosso, Stefano ;
Lemmens, Valery E. P. P. ;
Elferink, Marloes A. G. ;
Tomsic, Sonja ;
Zagar, Tina ;
Lopez de Munain Marques, Arantza ;
Marcos-Gragera, Rafael ;
Puigdemont, Montse ;
Galceran, Jaume ;
Carulla, Maria ;
Sanchez-Gil, Antonia ;
Chirlaque, Maria-Dolores ;
Hoffmeister, Michael ;
Brenner, Hermann .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08) :711-723
[6]   Incidence and Mortality of Proximal and Distal Colorectal Cancer in Germany Trends in the Era of Screening Colonoscopy [J].
Cardoso, Rafael ;
Zhu, Anna ;
Guo, Feng ;
Heisser, Thomas ;
Hoffmeister, Michael ;
Brenner, Hermann .
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2021, 118 (16) :281-+
[7]   Screen detection is a survival predictor independent of pathological grade in colorectal cancer. A prospective cohort study [J].
Chan, Yen Ming ;
MacKay, Craig ;
Ritchie, Duncan T. ;
Scott, Neil ;
Parnaby, Craig ;
Murray, Graeme, I ;
Ramsay, George .
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2021, 19 (01) :20-26
[8]  
Gemeinsamer Bundesausschuss, 2022, Richtlinie des Gemeinsamen Bundesausschusses fur organisierte Krebsfruherkennungsprogramme
[9]  
Haug U., 2020, DATABASES PHARMACOEP, P119, DOI DOI 10.1007/978-3-030-51455-6_8